Scinai Immunotherapeutics Ltd. announced that it will receive $1,694,259 in funding on December 29, 2023. The company will issue Convertible Preferred Shares in the transaction. The company will issue securities pursuant to exemption provided under Regulation D. In connection with the issuance of warrants to purchase up to 5,213,104 American Depositary Shares ("ADSs"), each representing 400 ordinary shares, no par value, of the Company at an exercise price of $0.65 per ADS.